Issue 8, 2011

Boron-containing inhibitors of synthetases

Abstract

The use of boron in small-molecule pharmaceuticals is increasing. Boron's ubiquitous occurrence in nature and the recent success of a boronic acid drug (VelcadeĀ®) in the clinic have alleviated many concerns over its use in pharmaceuticals. In addition, the unique physicochemical properties of boronic acids make them an attractive addition to the medicinal chemists toolbox. This tutorial review will discuss these properties and potential benefits for anyone interested in finding novel enzyme inhibitors. An exceptional class of boronic acids, the oxaboroles, will be highlighted and their properties and uses will be discussed in detail. Finally, the current paradigm for the reaction of boronic acids with enzyme nucleophiles will be summarized.

Graphical abstract: Boron-containing inhibitors of synthetases

Article information

Article type
Tutorial Review
Submitted
01 Oct 2010
Accepted
11 Jan 2011
First published
07 Feb 2011

Chem. Soc. Rev., 2011,40, 4279-4285

Boron-containing inhibitors of synthetases

S. J. Baker, J. W. Tomsho and S. J. Benkovic, Chem. Soc. Rev., 2011, 40, 4279 DOI: 10.1039/C0CS00131G

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements